Ketamine for Trauma and PTSD – Interview with Dr. Harrison Irons from Southern Ketamine and Wellness

by | May 16, 2022 | 2 comments

We work with many providers in the area to make sure that our clients receive the best care for their unique issue. One of the providers in the area of medical IV Ketamine is Southern Ketamine and Wellness. Dr. Harrison Irons was kind enough to sit down with us and explain the process for receiving ketamine treatment. Ketamine infusions are used in the treatment of PTSD, panic disorders, dissociation, dopamine disorders, mood disorders and the management of chronic pain.

Bibliography:

Feder, Adriana, et al. “Efficacy of Intravenous Ketamine for Treatment of Chronic Post-Traumatic Stress Disorder: A Randomized Clinical Trial.” JAMA Psychiatry, vol. 71, no. 6, 2014, pp. 681-688.
Dore, Jeffrey, et al. “Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.” Journal of Psychoactive Drugs, vol. 51, no. 2, 2019, pp. 189-198.
Andrade, Chittaranjan. “Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.” The Journal of Clinical Psychiatry, vol. 78, no. 4, 2017, pp. 393-402.
Goldberg, Mark E., et al. “Use of Ketamine in Pain Management.” Acta Anaesthesiologica Scandinavica, vol. 54, no. 6, 2010, pp. 672-683.
Jelen, Leszek A., et al. “Ketamine: A Promising Novel Antidepressant.” The International Journal of Neuropsychopharmacology, vol. 24, no. 1, 2021, pp. 77-88.

Further Reading:

Schoevers, Robert A., et al. “Adding Psychotherapy to Antidepressant Medication in Depression and Anxiety Disorders: A Meta-Analysis.” World Psychiatry, vol. 19, no. 1, 2020, pp. 77-93.
Arias, Andrew J., et al. “Pharmacology of Ibogaine and Noribogaine.” The Psychedelic Medicine, Edited by Michael P. Bogenschutz, Humana Press, 2018, pp. 145-181.
Sanacora, Gerard, et al. “Targeting the Glutamatergic System to Develop Novel, Improved Therapeutics for Mood Disorders.” Nature Reviews Drug Discovery, vol. 7, no. 5, 2008, pp. 426-437.
Zorumski, Charles F., et al. “Ketamine: NMDA Receptors and Beyond.” The Journal of Clinical Psychiatry, vol. 77, no. 7, 2016, e848-e852.
Mathew, Sanjay J., and Jos茅 A. Gonz谩lez-Heydrich. “Clinical Efficacy and Mechanisms of Ketamine for Depression and Pain: Insights from Neuroscience.” The American Journal of Psychiatry, vol. 177, no. 1, 2020, pp. 5-7.

What is The Golden Shadow In Jungian Psychology?

What is The Golden Shadow In Jungian Psychology?

Reclaiming the Golden Shadow: Integrating Our Disowned Potential In my work as a therapist, I often see this dynamic play out with my clients. They may come into therapy feeling fundamentally flawed, unworthy, or incapable in some way. Yet as they talk about the...

Theodore M. Porter and the Critique of Quantification:

Theodore M. Porter and the Critique of Quantification:

Implications Theodore Porter's Thinking in Psychotherapy and Mental Health Who is Theodore Porter? In his seminal work "Trust in Numbers: The Pursuit of Objectivity in Science and Public Life," historian of science Theodore Porter offers a compelling analysis of the...

2 Comments

    • Joel Blackstock

      Thank you please check out the youtube for more.

Submit a Comment

Your email address will not be published. Required fields are marked *